Antiphospholipid syndrome and the idiotypic network

Area of Science:

• Immunology
• Rheumatology
• Pathogenesis of Autoimmune Diseases

Background:

• Antiphospholipid syndrome (APS) is characterized by recurrent thrombosis and pregnancy complications.
• Monoclonal anticardiolipin antibodies (aCL) are implicated in APS pathogenesis.
• Understanding the pathogenic potential of specific aCL is crucial for APS management.

Purpose of the Study:

• To investigate the pathogenic potential of monoclonal anticardiolipin antibodies (aCL) derived from antiphospholipid syndrome (APS) patients.
• To establish an experimental model of APS using these monoclonal aCL.
• To compare the effects of different monoclonal aCL on serological and clinical manifestations.

Main Methods:

• Production of monoclonal aCL from APS patient lymphocytes via EBV transformation and somatic cell hybridization.
• Immunization of BALB/c mice with monoclonal aCL (EY2C9 and TM1B9).
• Monitoring of serological markers (antiphospholipid antibody titers, activated partial thromboplastin time) and clinical outcomes (fetal resorption rate).

Main Results:

• Monoclonal antibody EY2C9, weakly binding to phospholipids, induced sustained high titers of antiphospholipid antibodies and prolonged activated partial thromboplastin time (APTT) in mice.
• Mice immunized with EY2C9 exhibited a significantly increased fetal resorption rate (36.8%).
• Monoclonal antibody TM1B9, which did not react with phospholipids, induced only moderate antiphospholipid antibody titers and no prolonged APTT or increased fetal resorption.

Conclusions:

• Monoclonal anticardiolipin antibodies derived from APS patients possess pathogenic potential.
• These antibodies can dysregulate the immune system, leading to characteristic APS manifestations.
• The experimental model confirms the role of specific aCL in APS pathogenesis and associated complications.